Orphazyme A/S (CPH:ORPHA), a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, announced on Tuesday the creation of a US subsidiary, based in Newton, Massachusetts.
This subsidiary, named Orphazyme US Inc, will directly support the US market to establish closer relationships with the medical, patient and financial communities, as the company expands its development programme and global reach.
Also, the company announced that Paul Merrigan will head Orphazyme US Inc as the US president, in addition to his responsibilities as chief commercial officer.
According to the company, the opening of a subsidiary in the US is a significant step in its strategy to increase its efforts in developing partnerships and building relationships with the key stakeholders of researchers, healthcare providers and patient organisations within the US healthcare market and gradually increase its connections with the investor community.
The company added that it decided to put down its roots and grow its business in the greater Boston area because it is the cradle of the rare disease biopharmaceutical industry, its proximity to prestigious academic institutions and its access to highly qualified talent.
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial